The antibiotics market

Hamad, Bashar

doi:10.1038/nrd3267

Cited by 256 publications

(156 citation statements)

References 3 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…[3] Although numerous chemically modified derivatives entered the market in recent years, real innovation only occurred in the last 10 years when new classes of antibiotics were approved for clinical use (oxazolidinones, lipopeptides and mutilins). [4,11] The diminished interest to develop new antibiotics and the rapidly increasing emergence of resistance led to the highly prevalent problem that for an increasing number of multidrug-resistant (MDR) and pandrugresistant (PDR) bacteria no effective therapeutic treatment is available. [4] An essential cause for the emergence of antimicrobial resistance is the extensive use of antibiotics, leading to treatment failure, a reduced range of therapeutic options for consecutive bacterial infections and ultimately a serious threat for the patient.…”

Section: Antibiotics and Resistance -The Microbiological Tw Insmentioning

confidence: 99%

In vivo Evaluation of FimH Antagonists – A Novel Class of Antimicrobials for the Treatment of Urinary Tract Infection

Abgottspon¹,

Ernst

2012

Chimia

View full text Add to dashboard Cite

The discovery of antimicrobials as β-lactam antibiotics or aminoglycosides revolutionized the treatment of infectious diseases. However, the extensive use rapidly created the problem of resistant pathogens, which are increasingly difficult to treat. FimH antagonists are a new class of antimicrobials, which target the bacterial adhesion to urothelial cells, a crucial first step in the establishment of urinary tract infections. Because of their different mode of action, FimH antagonists neither kill nor inhibit the growth of bacteria, they should have a reduced potential to generate resistant strains. This mini-review outlines the main problems associated with increasing development of antimicrobial resistance. Furthermore, it summarizes the currently available in vivo studies in mice for the treatment of urinary tract infections conducted with FimH antagonists.

show abstract

Section: Antibiotics and Resistance -The Microbiological Tw Insmentioning

confidence: 99%

In vivo Evaluation of FimH Antagonists – A Novel Class of Antimicrobials for the Treatment of Urinary Tract Infection

Abgottspon¹,

Ernst

2012

Chimia

View full text Add to dashboard Cite

show abstract

“…Although sounding attractive, the effort to restrict antibiotic use seems counter to their importance, introduces guilt into even their most legitimate of uses, challenges the prevailing practices of initial empirical best guess therapy and prophylaxis deployment, and produces additional disincentives to antibiotic development. Although such initiatives highlight the pressing need for renewed antibiotic discovery and the fundamental importance of antibiotics in modern medicine (9), it has done little to define new approaches that directly address the underlying problem of evolutionarily driven and acquired resistance. The mechanisms of resistance are ancient and increasingly accumulating in pathogenic bacteria, which have now assimilated large elements of this bacterial resistome (10,11).…”

mentioning

confidence: 99%

Peripheral modifications of [Ψ[CH ₂ NH]Tpg ⁴ ]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics

Okano

Isley

Boger

2017

Proc. Natl. Acad. Sci. U.S.A.

176

215

View full text Add to dashboard Cite

Significance In a quest for antibiotics that may display durable clinical lifetimes, analogs of the glycopeptide antibiotics, including vancomycin, have been designed that not only directly overcome the molecular basis of existing vancomycin resistance but also contain two added peripheral modifications that endow them with two additional independent mechanisms of actions not found in the parent antibiotics. It is shown that such peripherally and binding pocket-modified vancomycin analogs display little propensity for acquired resistance by vancomycin-resistant Enterococci and that both their antimicrobial potency and durability against such challenges follow trends (three > two > one mechanisms of action) that are now predictable.

show abstract

“…However, while there clearly has been some success, both industry insiders and external analysts agree that current approaches to incentivising drug development are not sufficiently enticing to the pharmaceutical industry (Hamad 2010;Osborne 2013). The numbers support the view that industry commitment is patchy at best.…”

Section: Attempts To Boost Innovationmentioning

confidence: 64%

The Political and Ethical Challenge of Multi-Drug Resistant Tuberculosis

et al. 2015

View full text Add to dashboard Cite

This article critically examines current responses to multi-drug resistant tuberculosis and argues that bioethics needs to be willing to engage in a more radical critique of the problem than is currently offered. In particular, we need to focus not simply on market-driven models of innovation and anti-microbial solutions to emergent and re-emergent infections such as TB. The global community also needs to address poverty and the structural factors that entrench inequalities-thus moving beyond the orthodox medical/public health frame of reference. The problem of drug-resistant tuberculosisTwenty years after tuberculosis (TB) was declared a global public health emergency, it remains a leading infectious cause of death worldwide. TB also remains primarily a disease of poverty; higher rates of incidence follow in lock step with social and economic disadvantage. Two billion people are known to be infected with Mycobacterium tuberculosis. In its most recent report, The World Health Organization (2012) estimated that 8.6 million people develop TB each year and 1.3 million people die from active infection -the vast majority amongst the poor and marginalized in low-and middle-income countries.Data from surveillance programs and drug resistance surveys suggests that almost 4 percent of newly diagnosed cases and 20 percent of re-activated infections are caused by multi-drug resistant strains [MDR-TB] of the bacterium. About 630,000 (roughly 10 percent) of these MDR-TB cases exhibit extensive drug resistance [XDR-TB], which means that at least one of the two most potent first-line TB medications

show abstract

The antibiotics market

Cited by 256 publications

References 3 publications

In vivo Evaluation of FimH Antagonists – A Novel Class of Antimicrobials for the Treatment of Urinary Tract Infection

In vivo Evaluation of FimH Antagonists – A Novel Class of Antimicrobials for the Treatment of Urinary Tract Infection

Peripheral modifications of [Ψ[CH ₂ NH]Tpg ⁴ ]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics

The Political and Ethical Challenge of Multi-Drug Resistant Tuberculosis

Contact Info

Product

Resources

About

The antibiotics market

Cited by 256 publications

References 3 publications

In vivo Evaluation of FimH Antagonists – A Novel Class of Antimicrobials for the Treatment of Urinary Tract Infection

In vivo Evaluation of FimH Antagonists – A Novel Class of Antimicrobials for the Treatment of Urinary Tract Infection

Peripheral modifications of [Ψ[CH 2 NH]Tpg 4 ]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics

The Political and Ethical Challenge of Multi-Drug Resistant Tuberculosis

Contact Info

Product

Resources

About

Peripheral modifications of [Ψ[CH ₂ NH]Tpg ⁴ ]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics